Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl H June

Showing results (401-410 of 460) with videos related to

Pageof 46
Sort By:
Blood|February 22, 2013
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantationDaniel H Fowler, Miriam E Mossoba, Seth M Steinberg, et al.
Nature Cancer|September 22, 2023
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancerSara Bobisse, Valentina Bianchi, Janos L Tanyi, et al.
Nature Biotechnology|May 4, 2020
Human chimeric antigen receptor macrophages for cancer immunotherapyMichael Klichinsky, Marco Ruella, Olga Shestova, et al.
Blood|September 14, 2021
A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myelomaMuzaffar H Qazilbash, Neeraj Y Saini, Soung-Chul Cha, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 15, 2023
Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapyMireia Uribe-Herranz, Silvia Beghi, Marco Ruella, et al.
Cancer Cell|December 13, 2022
Expression of inducible factors reprograms CAR-T cells for enhanced function and safetyAnže Smole, Alexander Benton, Mathilde A Poussin, et al.
Blood|June 18, 2013
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanomaGerald P Linette, Edward A Stadtmauer, Marcela V Maus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2022
Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19Caroline Diorio, Rawan Shraim, Regina Myers, et al.
Cancer Immunology Research|November 8, 2017
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast CancerJulia Tchou, Yangbing Zhao, Bruce L Levine, et al.
Cancer Discovery|April 15, 2016
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic LeukemiaDavid T Teachey, Simon F Lacey, Pamela A Shaw, et al.
Pageof 46

Showing results (401-410 of 460) with videos related to

Sort By:
Pageof 46
Blood|February 22, 2013
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantationDaniel H Fowler, Miriam E Mossoba, Seth M Steinberg, et al.
Nature Cancer|September 22, 2023
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancerSara Bobisse, Valentina Bianchi, Janos L Tanyi, et al.
Nature Biotechnology|May 4, 2020
Human chimeric antigen receptor macrophages for cancer immunotherapyMichael Klichinsky, Marco Ruella, Olga Shestova, et al.
Blood|September 14, 2021
A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myelomaMuzaffar H Qazilbash, Neeraj Y Saini, Soung-Chul Cha, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 15, 2023
Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapyMireia Uribe-Herranz, Silvia Beghi, Marco Ruella, et al.
Cancer Cell|December 13, 2022
Expression of inducible factors reprograms CAR-T cells for enhanced function and safetyAnže Smole, Alexander Benton, Mathilde A Poussin, et al.
Blood|June 18, 2013
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanomaGerald P Linette, Edward A Stadtmauer, Marcela V Maus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2022
Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19Caroline Diorio, Rawan Shraim, Regina Myers, et al.
Cancer Immunology Research|November 8, 2017
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast CancerJulia Tchou, Yangbing Zhao, Bruce L Levine, et al.
Cancer Discovery|April 15, 2016
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic LeukemiaDavid T Teachey, Simon F Lacey, Pamela A Shaw, et al.
Pageof 46